Pain Therapeutics (NASDAQ:PTIE) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.40) EPS for the quarter, Bloomberg Earnings reports.

A number of equities research analysts have recently commented on PTIE shares. Zacks Investment Research cut Pain Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 14th. Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 17th.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.